HRP20161717T1 - Nalmefen za smanjenje konzumacije alkohola u specifičnim ciljnim populacijama - Google Patents

Nalmefen za smanjenje konzumacije alkohola u specifičnim ciljnim populacijama Download PDF

Info

Publication number
HRP20161717T1
HRP20161717T1 HRP20161717TT HRP20161717T HRP20161717T1 HR P20161717 T1 HRP20161717 T1 HR P20161717T1 HR P20161717T T HRP20161717T T HR P20161717TT HR P20161717 T HRP20161717 T HR P20161717T HR P20161717 T1 HRP20161717 T1 HR P20161717T1
Authority
HR
Croatia
Prior art keywords
nalmefene
alcohol
longer
use according
patient
Prior art date
Application number
HRP20161717TT
Other languages
English (en)
Croatian (hr)
Inventor
Lars Torup
Afsaneh ABBARIKI
Anna BLADSTRÖM
Christine PERSSON
Didier Meulien
Per SØRENSEN
Thomas Jon Jensen
Jette Buch Østergaard
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48703496&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20161717(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of HRP20161717T1 publication Critical patent/HRP20161717T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
HRP20161717TT 2012-06-27 2013-06-27 Nalmefen za smanjenje konzumacije alkohola u specifičnim ciljnim populacijama HRP20161717T1 (hr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201261664804P 2012-06-27 2012-06-27
US201261721539P 2012-11-02 2012-11-02
US201261736740P 2012-12-13 2012-12-13
US201361788810P 2013-03-15 2013-03-15
PCT/EP2013/063461 WO2014001427A1 (en) 2012-06-27 2013-06-27 Nalmefene for reduction of alcohol consumption in specific target populations
EP13732471.1A EP2866808B1 (en) 2012-06-27 2013-06-27 Nalmefene for reduction of alcohol consumption in specific target populations

Publications (1)

Publication Number Publication Date
HRP20161717T1 true HRP20161717T1 (hr) 2017-02-10

Family

ID=48703496

Family Applications (4)

Application Number Title Priority Date Filing Date
HRP20161717TT HRP20161717T1 (hr) 2012-06-27 2013-06-27 Nalmefen za smanjenje konzumacije alkohola u specifičnim ciljnim populacijama
HRP20250329TT HRP20250329T1 (hr) 2012-06-27 2013-06-27 Nalmefen za smanjenje konzumacije alkohola u specifično ciljnim populacijama
HRP20230762TT HRP20230762T8 (hr) 2012-06-27 2013-06-27 Nalmefen za smanjenje konzumacije alkohola u specifičnim ciljnim populacijama
HRP20180363TT HRP20180363T1 (hr) 2012-06-27 2018-02-28 Nalmefen, namijenjen smanjivanju potrošnje alkohola kod specifičnih ciljanih populacija

Family Applications After (3)

Application Number Title Priority Date Filing Date
HRP20250329TT HRP20250329T1 (hr) 2012-06-27 2013-06-27 Nalmefen za smanjenje konzumacije alkohola u specifično ciljnim populacijama
HRP20230762TT HRP20230762T8 (hr) 2012-06-27 2013-06-27 Nalmefen za smanjenje konzumacije alkohola u specifičnim ciljnim populacijama
HRP20180363TT HRP20180363T1 (hr) 2012-06-27 2018-02-28 Nalmefen, namijenjen smanjivanju potrošnje alkohola kod specifičnih ciljanih populacija

Country Status (35)

Country Link
US (4) US20140005216A1 (enExample)
EP (5) EP3345604B1 (enExample)
JP (3) JP6258933B2 (enExample)
KR (1) KR20150023396A (enExample)
CN (1) CN104411313A (enExample)
AU (1) AU2013283281B2 (enExample)
BR (1) BR112014032555A2 (enExample)
CA (1) CA2874703C (enExample)
CL (1) CL2014003484A1 (enExample)
CO (1) CO7160087A2 (enExample)
CY (3) CY1118579T1 (enExample)
DK (3) DK2866808T3 (enExample)
EA (1) EA029908B1 (enExample)
ES (4) ES2609122T3 (enExample)
FI (1) FI3345604T3 (enExample)
HK (1) HK1255683A1 (enExample)
HR (4) HRP20161717T1 (enExample)
HU (4) HUE036272T2 (enExample)
IL (1) IL236035B (enExample)
LT (3) LT3345604T (enExample)
ME (2) ME03030B (enExample)
MX (1) MX371373B (enExample)
MY (1) MY166914A (enExample)
NZ (1) NZ702191A (enExample)
PH (1) PH12014502798A1 (enExample)
PL (4) PL4223296T3 (enExample)
PT (3) PT3345604T (enExample)
RS (2) RS55456B1 (enExample)
RU (1) RU2665373C2 (enExample)
SG (1) SG11201408704WA (enExample)
SI (3) SI3345604T1 (enExample)
SM (3) SMT201600471T1 (enExample)
UA (1) UA114199C2 (enExample)
WO (1) WO2014001427A1 (enExample)
ZA (1) ZA201409525B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140005216A1 (en) 2012-06-27 2014-01-02 H. Lundbeck A/S Nalmefene for reduction of alcohol consumption in specific target populations
WO2014170353A1 (en) * 2013-04-17 2014-10-23 H. Lundbeck A/S Nalmefene for treatment of patients with sleep disorder
SG10201809280PA (en) 2014-04-22 2018-11-29 Otsuka Pharma Co Ltd Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
US20170071590A1 (en) * 2015-09-10 2017-03-16 Suture Armor Llc Suture anchor
KR102699603B1 (ko) 2018-04-20 2024-08-29 삼성전자주식회사 반도체 메모리 소자

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3814768A (en) 1971-11-26 1974-06-04 Lewenstein E 6-methylene-6-desoxy dihydro morphine and codeine derivatives and pharmaceutically acceptable salts
US4535157A (en) 1983-11-01 1985-08-13 Key Pharmaceuticals, Inc. Process for making 6-desoxy-6-methylenenaloxone and 6-desoxy-6-methylenenaltrexone
US5086058A (en) * 1990-06-04 1992-02-04 Alko Ltd. Method for treating alcoholism with nalmefene
PL368612A1 (en) * 2001-08-14 2005-04-04 Biotie Therapies Corporation Method of treating alcoholism or alcohol abuse
UA102128C2 (en) * 2008-12-05 2013-06-10 Х. Луннбек А/С Nalmefene hydrochloride dihydrate
HRP20160110T1 (hr) 2009-05-25 2016-03-11 H. Lundbeck A/S Priprema nalmefen hidroklorida iz naltreksona
HRP20170379T1 (hr) 2010-11-05 2017-05-05 H. Lundbeck A/S Postupak proizvodnje naltreksona
TR201803744T4 (tr) 2011-03-31 2018-07-23 Imuneks Farma Ilac Sanayi Ve Ticaret Anonim Sirketi Skleroderma tedavisinde kullanım için naltrekson içeren bileşimler.
US20140005216A1 (en) 2012-06-27 2014-01-02 H. Lundbeck A/S Nalmefene for reduction of alcohol consumption in specific target populations

Also Published As

Publication number Publication date
SMT201800164T1 (it) 2018-07-17
LT3138564T (lt) 2018-04-10
HUE036272T2 (hu) 2018-06-28
CY1120097T1 (el) 2018-12-12
ES2950492T3 (es) 2023-10-10
PT2866808T (pt) 2017-01-03
US20180028526A1 (en) 2018-02-01
RU2665373C2 (ru) 2018-08-29
SI2866808T1 (sl) 2017-01-31
MX2014015488A (es) 2015-03-06
HRP20230762T8 (hr) 2024-01-05
AU2013283281B2 (en) 2017-04-20
EP4541421A2 (en) 2025-04-23
DK3345604T3 (da) 2023-07-24
US20140005217A1 (en) 2014-01-02
SMT201600471T1 (it) 2017-03-08
ES3014068T3 (en) 2025-04-16
EP4223296A2 (en) 2023-08-09
CY1118579T1 (el) 2017-07-12
CY1126140T1 (el) 2023-11-15
RS57046B1 (sr) 2018-05-31
HRP20250329T1 (hr) 2025-05-09
SI3345604T1 (sl) 2023-08-31
WO2014001427A1 (en) 2014-01-03
SG11201408704WA (en) 2015-01-29
EP3345604A1 (en) 2018-07-11
EP3138564A1 (en) 2017-03-08
HK1208185A1 (en) 2016-02-26
JP2019163275A (ja) 2019-09-26
PT3345604T (pt) 2023-07-17
RU2014151156A (ru) 2016-08-20
PL3345604T3 (pl) 2023-08-28
US20160375007A1 (en) 2016-12-29
ES2663532T3 (es) 2018-04-13
LT2866808T (lt) 2017-01-10
HUE070621T2 (hu) 2025-06-28
EP2866808A1 (en) 2015-05-06
CA2874703C (en) 2022-08-23
PT3138564T (pt) 2018-04-03
HUE063313T2 (hu) 2024-01-28
PL3138564T3 (pl) 2018-06-29
DK3138564T3 (en) 2018-03-26
EP4223296A3 (en) 2023-09-27
UA114199C2 (uk) 2017-05-10
EA201492152A1 (ru) 2015-11-30
US20140005216A1 (en) 2014-01-02
LT3345604T (lt) 2023-08-10
HRP20180363T1 (hr) 2018-04-20
JP2018039810A (ja) 2018-03-15
ME02587B (me) 2017-06-20
PL2866808T3 (pl) 2017-04-28
AU2013283281A1 (en) 2014-12-11
CN104411313A (zh) 2015-03-11
ME03030B (me) 2018-10-20
HUE031110T2 (en) 2017-06-28
EP4223296C0 (en) 2025-01-29
CA2874703A1 (en) 2014-01-03
JP6258933B2 (ja) 2018-01-10
BR112014032555A2 (pt) 2017-06-27
HK1255683A1 (en) 2019-08-23
JP6857684B2 (ja) 2021-04-14
EP3138564B1 (en) 2018-01-31
PL4223296T3 (pl) 2025-04-14
ES2609122T3 (es) 2017-04-18
US10034874B2 (en) 2018-07-31
HRP20230762T1 (hr) 2023-10-13
NZ702191A (en) 2017-06-30
EP3345604B1 (en) 2023-06-07
ZA201409525B (en) 2016-08-31
FI3345604T3 (fi) 2023-07-28
MX371373B (es) 2020-01-28
IL236035B (en) 2018-12-31
CL2014003484A1 (es) 2015-02-27
IL236035A0 (en) 2015-01-29
SI3138564T1 (en) 2018-04-30
CO7160087A2 (es) 2015-01-15
SMT201600471B (it) 2017-03-08
JP2015521647A (ja) 2015-07-30
EP4541421A3 (en) 2025-06-18
EP4223296B1 (en) 2025-01-29
KR20150023396A (ko) 2015-03-05
EP2866808B1 (en) 2016-11-02
US9642849B2 (en) 2017-05-09
EA029908B1 (ru) 2018-05-31
PH12014502798A1 (en) 2015-02-09
DK2866808T3 (en) 2017-01-16
MY166914A (en) 2018-07-24
RS55456B1 (sr) 2017-04-28

Similar Documents

Publication Publication Date Title
SG10201407013QA (en) Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
HRP20161717T1 (hr) Nalmefen za smanjenje konzumacije alkohola u specifičnim ciljnim populacijama
HRP20241461T1 (hr) Aprocitentan za uporabu u liječenju hipertenzije i povezanih bolesti u kombinaciji s valsartanom
HRP20171256T1 (hr) Farmaceutski pripravci karbetocina
JP2013514984A5 (enExample)
FI3936130T3 (fi) Valbenatsiinin annostusohjelma hyperkineettisten liikehäiriöiden hoitoon
HRP20180942T1 (hr) Liječenje negativnih simptoma shizofrenije s (r)-7-kloro-n-(kinuklidin-3-il)benzo[b]tiofen-2-karboksamidom i njegovim farmaceutski prihvatljivim solima
JP2010222367A5 (enExample)
HRP20240121T1 (hr) Kontracepcija na bazi drospirenona za pacijenticu s viškom tjelesne težine
SI2501234T1 (en) Methods and compositions for treating symptoms associated with post-traumatic stress disorder using cyclobenzaprine
PE20081578A1 (es) Formulacion en polvo de valganciclovir
HRP20250779T1 (hr) Režim za doziranje sakubitril-valsartana za liječenje kroničnog sistoličnog zatajenja srca
JP2018527305A5 (enExample)
AR063538A1 (es) Tratamiento de la enfermedad de parkinson
JP2018039810A5 (enExample)
BR112014014795A2 (pt) sistema de pélete de multiunidade de liberação imediata
HRP20171678T1 (hr) Postupci za smanjenje prejedanja ili kompulzivnog jedenja
JP2013523628A5 (enExample)
PH12013500552A1 (en) Enhanced transbuccal drug delivery system and compositions
HRP20230735T1 (hr) Betahistin, ili njegova farmaceutski prihvatljiva sol, i inhibitor monoamin oksidaze, za uporabu u liječenju ili prevenciji jednog ili više simptoma vrtoglavice kod subjekta
UY33499A (es) Formulaciones que comprenden particulas finas recubiertas
ES2678122T3 (es) Comprimidos bucales mucoadherentes para el tratamiento del herpes orofacial
HRP20200155T1 (hr) Farmaceutski pripravak koji obuhvaća drospirenon i kontracepcijski komplet
Ince Methylphenidate/valproate
GUO et al. Clinical study on desmopressin acetate therapy in patients with adipsic hypernatremia: Five cases report